中文摘要：

目的：观察茵栀黄口服液对血型抗体高效价孕妇免疫性抗体IgG亚型的影响,评价茵栀黄口服液用于早期干预治疗母婴血型不合新生儿溶血病的药物作用机制。方法：选择2014-06-2015-12于我院检查的高效价孕妇70例,将血型免疫抗体效价ABO≥256,Rh血型抗-D效价≥64的孕妇按自愿原则随机分成常规治疗组32例和茵栀黄口服液治疗组38例。常规治疗组：VC 3g,VE 100mg 1次/d,吸氧2次/d,每次20~30min,1个月作为1个疗程;茵栀黄口服液治疗组在常规治疗的基础上服用茵栀黄口服液20ml/次,3次/d,治疗前后检测孕妇血型抗体效价及IgG亚型的变化,并对治疗的安全性及不良反应情况进行综合评价。结果：常规治疗组治疗前后各项指标变化不明显,茵栀黄口服液治疗组抗体效价及IgG亚型的含量明显降低,2组比较差异有统计学意义（P〈0.05）;血型抗体IgG各亚型均有不同程度降低,2组均未见明显不良反应。结论：茵栀黄口服液用于孕期干预治疗母婴血型不合新生儿溶血病具有很好的效果,对孕妇和胎儿是安全的,值得临床推广应用。

英文摘要：

Objective：To observe the influence of Yinzhihuang oral liquid on the blood type antibody IgG sub- sets of the pregnant woman, and assess the medical efficacy and safety in early intervention treatment of hemolytic disease of the newborn （HDN）. Method：From Jun. 2014 to Dec. 2015 in our hospital,70 cases of high antibody titer pregnant women （ABO≥256,Rh≥16） were randomly divided into general treatment group （32 cases） and Yinzhihuang treatment group （38 cases）. The general group were given VC 3 g, VE 100 mg q. d ,oxygen uptake bid. 20 to 30 min every time, therapy 20 d every month. The Yinzhihuang treatment group were given Yinzhi- huang oral liquid treatment base on the general group, 20 ml rid . The safety and the adverse reaction were ob- served at the same time in two groups. The mean serum blood group antibody titer, the antibody IgG subsets and states of foetus intrauterine growth were compared and analyzed. Result：The total serum antibody titer and the an- tibody IgG subsets states in Yinzhihuang treatment group were better than those of general group. The differences of two treatment groups had statistical significance（P〈0.05）. The obvious adverse reaction was not observed in two groups. Conclusion： Yinzhihuang oral liquid might be a safe and effective means for early interventions in treat- ment of blood type incompatible HDN, which might be good for early intervention treatment of HDN.